LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro to Present at H.C. Wainwright BioConnect 2022 Conference
03 janv. 2022 07h00 HE | Recro Pharma, Inc.
SAN DIEGO and GAINESVILLE, Ga., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro to Present at Stephens Annual Investment Conference
02 déc. 2021 07h00 HE | Recro Pharma, Inc.
SAN DIEGO and GAINESVILLE, Ga., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Reports Third Quarter 2021 Financial Results
09 nov. 2021 16h05 HE | Recro Pharma, Inc.
Acquisition of IriSys, Inc. Significantly Expands Customer Pipeline, Facilities and Capabilities Annual Revenue Guidance Increased to between $74 and $76 million Recorded Q3 2021 Revenues of...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro to Report Financial Results for Third Quarter 2021 on November 9, 2021
02 nov. 2021 16h05 HE | Recro Pharma, Inc.
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Enters Into Master Commercial Supply and Services Agreement With Otsuka
27 oct. 2021 07h00 HE | Recro Pharma, Inc.
Agreement Establishes Recro as Commercial Supplier for Otsuka Deal Validates Recro’s “Second Source” Strategy of Supporting Commercial Programs as U.S.-Based Supplier GAINESVILLE, Ga. and SAN...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Awarded Development and Manufacturing Contract by National Institutes of Health (NIH) to Support Novel Nasal Spray Analgesic
20 oct. 2021 07h00 HE | Recro Pharma, Inc.
GAINESVILLE, Ga. and SAN DIEGO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Reports Inducement Grants For New Staff
06 oct. 2021 07h00 HE | Recro Pharma, Inc.
EXTON, Penn. and SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Signs Renewable Energy Agreement With Georgia Power
21 sept. 2021 07h00 HE | Recro Pharma, Inc.
EXTON, Pa., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
08 sept. 2021 07h00 HE | Recro Pharma, Inc.; BioCorRx, Inc.
SAN DIEGO and ANAHEIM, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro to Host Webcast to Discuss Acquisition of San Diego-Based IRISYS
17 août 2021 07h00 HE | Recro Pharma, Inc.
Acquisition Expands Recro’s Global Customer Base and Service Offerings, Creates Bi-Coastal CDMO, Diversifies Pipeline and Revenue Sources, and Provides Additional Pathway for Continued Growth Webcast...